These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 33005037)

  • 1. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
    Marton A; Kaneko T; Kovalik JP; Yasui A; Nishiyama A; Kitada K; Titze J
    Nat Rev Nephrol; 2021 Jan; 17(1):65-77. PubMed ID: 33005037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
    Layton AT; Vallon V
    Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Bailey CJ
    Diabetes Obes Metab; 2019 Jun; 21(6):1291-1298. PubMed ID: 30762288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition and kidney protection.
    Nespoux J; Vallon V
    Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.
    Verma S
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S36-S44. PubMed ID: 31741439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation.
    Kitada K; Kidoguchi S; Nakano D; Nishiyama A
    J Pharmacol Sci; 2021 Nov; 147(3):245-250. PubMed ID: 34507633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
    Pecoits-Filho R; Perkovic V
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
    [No Abstract]   [Full Text] [Related]  

  • 15. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
    Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1481-1490. PubMed ID: 31377891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.